Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety

Twist joins leading AI stakeholders to help advance the development and deployment of safe, trustworthy AI under new U.S. Government safety institute

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce’s National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI.

“Biosecurity has been a priority for Twist since the inception of the company, and we continue to advance our biosecurity measures with the introduction of new technology and products to keep us at the forefront of biosecurity,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “As advancements are made in artificial intelligence and with the integral role that synthetic DNA plays in translating digital biological designs into physical constructs to advance therapeutic and materials development, we are committed to working with AISIC members, including industry, academia, government and others, to support the development of interoperable safety standards to advance research responsibly.”

The consortium includes more than 200 member companies and organizations that are on the frontlines of developing and using AI systems, as well as the civil society and academic teams that are building the foundational understanding of how AI can and will transform our society. These entities represent the nation’s largest companies and its innovative startups; creators of the world’s most advanced AI systems and hardware; key members of civil society and the academic community; and representatives of professions with deep engagement in AI’s use today. The consortium also includes state and local governments, as well as non-profits. The consortium will also work with organizations from like-minded nations that have a key role to play in setting interoperable and effective safety around the world.

The full list of consortium participants is available here.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the ability of Twist Bioscience to advance its biosecurity measures and support the development of interoperable safety standards. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period will depend heavily on the success of our existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604321380/en/